Carboplatin AUC Calculator

The Carboplatin AUC Calculator implements the Calvert formula for individualized carboplatin dosing based on target area under the concentration-time curve (AUC) and glomerular filtration rate (GFR). Carboplatin is a second-generation platinum chemotherapy agent widely used in the treatment of ovarian cancer, non-small cell lung cancer, head and neck cancers, testicular cancer, and numerous other solid tumors. Unlike most chemotherapy agents dosed by body surface area (BSA), carboplatin dosing is uniquely guided by renal function through the Calvert equation.

The Calvert formula, published by Calvert et al. in 1989, was a landmark contribution to individualized chemotherapy dosing: Dose (mg) = Target AUC × (GFR + 25). This equation accounts for the fact that carboplatin is primarily eliminated by renal excretion (approximately 65-70% unchanged in urine), with a non-renal clearance of approximately 25 mL/min. By incorporating individual GFR, the formula produces consistent drug exposure (AUC) across patients with varying renal function, reducing both under-dosing and toxicity.

Target AUC values are regimen-specific. For most combination regimens (e.g., with paclitaxel or gemcitabine), AUC 5-6 is standard. For single-agent carboplatin or dose-dense regimens, AUC 6-7 may be used. For heavily pretreated patients or those with borderline renal function, AUC 4-5 may be appropriate. The AUC target is a critical clinical decision made by the treating oncologist based on the treatment protocol, prior therapy, and patient factors.

The choice of GFR method significantly impacts the calculated dose. The original Calvert validation used measured GFR (51Cr-EDTA clearance). When estimated GFR methods (Cockcroft-Gault, CKD-EPI, or Jelliffe equations) are used instead, systematic overestimation of GFR can lead to overdosing. The FDA issued a safety communication in 2010 recommending that when using estimated GFR, the value should be capped at 125 mL/min to prevent excessive dosing, particularly in patients with high creatinine clearance (young, muscular, or obese patients).

In clinical practice, the choice between measured and estimated GFR remains institution-dependent. Many major cancer centers use measured GFR (nuclear medicine scan or iohexol clearance) for initial dosing in curative-intent regimens, while estimated GFR is commonly used for palliative chemotherapy and dose adjustments. The Cockcroft-Gault equation remains the most commonly used estimator for Calvert dosing, though CKD-EPI may be used at some institutions.

Carboplatin's primary dose-limiting toxicity is myelosuppression, particularly thrombocytopenia, which is AUC-dependent. Other toxicities include nausea/vomiting (moderate emetogenic risk), nephrotoxicity (much less than cisplatin), peripheral neuropathy, and allergic/hypersensitivity reactions (especially after multiple cycles). Maintaining the target AUC within the intended range optimizes the balance between efficacy and toxicity.

This calculator provides Calvert formula-based dosing with appropriate GFR capping when estimated GFR is used, supporting safe and accurate carboplatin dosing in oncology practice.

Important: Carboplatin should only be prescribed by or under the supervision of qualified oncologists. All doses should be verified against the specific treatment protocol being used.